Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

被引：52
|
作者：
Mizuno, Y
Yanagisawa, N
Kuno, S
Yamamoto, M
Hasegawa, K
Origasa, H
Kowa, H
机构：
[1] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Kanto Rosai Hosp, Kawasaki, Kanagawa, Japan
[3] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Sect, Kyoto, Japan
[4] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan
[5] Sagamihara Natl Hosp, Dept Neurol, Sagamihara, Kanagawa, Japan
[6] Toyama Med & Pharmaceut Univ, Fac Med, Div Biostat, Toyama, Japan
[7] Kitasato Univ, Tokyo, Japan
来源：
MOVEMENT DISORDERS | 2003年 / 18卷 / 10期
关键词：
Parkinson's disease; pramipexole; bromocriptine; levodopa; drug comparison; randomized controlled trial (RCT);
D O I：
10.1002/mds.10508
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (1311) group was included to enable determination of the noninferiority of PPX relative to 1311 as the standard treatment. (C) 2003 Movement Disorder Society.
引用
收藏
页码：1149 / 1156
页数：8
相关论文
共 50 条
  • [31] Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
    Barone, Paolo
    Poewe, Werner
    Albrecht, Stefan
    Debieuvre, Catherine
    Massey, Dan
    Rascol, Olivier
    Tolosa, Eduardo
    Weintraub, Daniel
    LANCET NEUROLOGY, 2010, 9 (06): : 573 - 580
  • [32] Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
    Lagalla, Giovanni
    Millevolte, Marzia
    Capecci, Marianna
    Provinciali, Leandro
    Ceravolo, Maria Gabriella
    MOVEMENT DISORDERS, 2006, 21 (05) : 704 - 707
  • [33] Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
    Asako Yoritaka
    Yasuko Kobayashi
    Tetsuo Hayashi
    Shinji Saiki
    Nobutaka Hattori
    Neurological Sciences, 2021, 42 : 4767 - 4770
  • [34] Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study
    Yoritaka, Asako
    Kobayashi, Yasuko
    Hayashi, Tetsuo
    Saiki, Shinji
    Hattori, Nobutaka
    NEUROLOGICAL SCIENCES, 2021, 42 (11) : 4767 - 4770
  • [35] Donepezil for dementia in Parkinson's disease: A randomized, double-blind, placebo-controlled, crossover study.
    Ravina, B
    Putt, M
    Siderowf, A
    Farrar, JT
    Gillespie, M
    Crawley, A
    Fernandez, H
    Treischmann, M
    Reichwein, S
    Simuni, T
    MOVEMENT DISORDERS, 2004, 19 (09) : 1132 - 1133
  • [36] Randomized, double-blind, placebo-controlled study of naltrexone for impulse control disorders in Parkinson's disease
    Weintraub, D.
    Xie, S. X.
    Stern, M.
    Hurtig, H.
    Siderowf, A.
    Minger, J.
    Papay, K.
    MOVEMENT DISORDERS, 2013, 28 : S141 - S142
  • [37] Mucuna pruriens therapy in Parkinson's disease: A double-blind, placebo-controlled, randomized, crossover study
    Cilia, R.
    Laguna, J.
    Cassani, E.
    Cereda, E.
    Pezzoli, G.
    MOVEMENT DISORDERS, 2015, 30 : S425 - S425
  • [38] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [39] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311
  • [40] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
12345